0RNK Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of MASH and other diseases in France, the United States, and Internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Inventiva S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.22 |
| 52 Week High | €3.50 |
| 52 Week Low | €1.46 |
| Beta | 0.97 |
| 1 Month Change | 40.61% |
| 3 Month Change | 37.02% |
| 1 Year Change | 7.33% |
| 3 Year Change | -63.51% |
| 5 Year Change | n/a |
| Change since IPO | -54.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RNK | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0.6% | 5.1% | 0.9% |
| 1Y | 7.3% | -15.3% | 0.3% |
Return vs Industry: 0RNK exceeded the UK Biotechs industry which returned -11.8% over the past year.
Return vs Market: 0RNK exceeded the UK Market which returned 1.1% over the past year.
Price Volatility
| 0RNK volatility | |
|---|---|
| 0RNK Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 10.9% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: 0RNK's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RNK's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 116 | Frederic Cren | www.inventivapharma.com |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of MASH and other diseases in France, the United States, and Internationally. It develops Lanifibranor, for the treatment of patients with metabolic dysfunction-associated steatohepatitis, a progressive, chronic liver disease, which is in Phase III clinical trial; and Odiparcil for the treatment of patients with mucopolysaccharidoses, or MPS, a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells. In addition, it has a pipeline of earlier stage programs in oncology and other diseases.
Inventiva S.A. Fundamentals Summary
| 0RNK fundamental statistics | |
|---|---|
| Market cap | €308.03m |
| Earnings (TTM) | -€184.21m |
| Revenue (TTM) | €14.09m |
21.9x
P/S Ratio-1.7x
P/E RatioIs 0RNK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RNK income statement (TTM) | |
|---|---|
| Revenue | €14.09m |
| Cost of Revenue | €1.40m |
| Gross Profit | €12.70m |
| Other Expenses | €196.91m |
| Earnings | -€184.21m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Sep 25, 2025
| Earnings per share (EPS) | -1.93 |
| Gross Margin | 90.09% |
| Net Profit Margin | -1,307.02% |
| Debt/Equity Ratio | -165.6% |
How did 0RNK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 08:21 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inventiva S.A. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jean-Jacques Le Fur | Bryan Garnier & Co |
| Edward Nash | Canaccord Genuity |
| Stephanie Lefebvre | Gilbert Dupont |